Drugs / PAVINETANT
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00867685 | Mar → Apr 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00696865 | May → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02865915 | Jul 2016 → Sep 2017 | polycystic ovary syndrome | Millendo Therapeutics US, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02668185 | Feb 2016 → Jan 2017 | — | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT01872078 | Jun 2013 → Jul 2014 | polycystic ovary syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00686998 | May 2008 → Mar 2009 | schizophrenia | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAVINETANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545233 ↗ |
| Known as | AZ-12472520 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545233 ↗ |
| Known as | AZ124752520 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545233 ↗ |
| Known as | AZ4901 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545233 ↗ |
| Known as | AZD 2624 | “Single dose of 40 mg AZD 2624 (2x20mg tablets), PO” NCT00867685 ↗ |
| Known as | AZD4901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01872078 ↗ |
| Known as | MLE4901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02865915 ↗ |
| Action | Inhibit | “AZD4901 (a specific neurokinin-3 [NK3] receptor antagonist)” PMID 27459523 ↗ Jul 20161“Neurokinin 3 receptor antagonist” CHEMBL3545233 ↗ |
| Modality | Small molecule | — CHEMBL3545233 ↗ |
| Route | Oral | “Oral Suspension” NCT00686998 ↗ |
| Target | TACR3 | “Neurokinin 3 receptor antagonist” CHEMBL3545233 ↗ |